Palisade Bio

Palisade Bio (Nasdaq: $PALI) is advancing next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases.

[Palisade Bio @PalisadeBio]

On Thursday, June 4th at 3:45 PM ET, JD Finley, CEO, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, will present at the Jefferies Global Healthcare Conference.

Register for the webcast here: https://t.co/aHaAJbMvkf

$PALI

[Palisade Bio @PalisadeBio]

JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer of Palisade Bio, will present at the Jefferies Global Healthcare Conference on Thursday, June 4th at 3:45 PM ET.

For details: https://t.co/LvUo0nYrDK

$PALI

[Palisade Bio @PalisadeBio]

Today is #WorldIBDDay!

At Palisade, we stand with the millions of people living with #IBD worldwide. We are committed to developing PALI-2108 for the potential treatment of #UlcerativeColitis and #CrohnsDisease. Learn about our pipeline: https://t.co/r8dX4vJ8qB

#IBDAwareness

[Palisade Bio @PalisadeBio]

“We continue to see a consistent and differentiated profile emerging for PALI-2108 across IBD,” –JD Finley, $PALI CEO. Palisade plans to advance into Ph. 2 development in #ulcerativecolitis & #Crohnsdisease. For recent highlights & anticipated milestones: https://t.co/WnbsoruiDE

[Palisade Bio @PalisadeBio]

Palisade today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Ph. 2 trial initiations. For details: https://t.co/WnbsoruiDE $PALI

[Palisade Bio @PalisadeBio]

Additional steady-state pharmacokinetic findings provide mechanistic support for previously reported PALI-2108 Phase 1b clinical activity and support PALI-2108’s potential as a once-daily, gut-targeted oral therapy. More info: https://t.co/4zMYNuNXoy

$PALI #DDW2026

[Palisade Bio @PalisadeBio]

“These additional pharmacokinetic and translational analyses further characterize the differentiated profile of PALI-2108," said Mitch Jones, MD, Ph.D., President & Chief Medical Officer of Palisade Bio. Read More: https://t.co/4zMYNuNXoy

$PALI #DDW2026

[Palisade Bio @PalisadeBio]

PALI-2108 Phase 1a/b data presented at #DDW2026 demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval, highlighting a differentiated profile. Learn more: https://t.co/4zMYNuNXoy $PALI

[Palisade Bio @PalisadeBio]

Palisade announced the presentation of additional Ph 1a/b analyses of PALI-2108, incl. delayed ileocolonic activation, high tissue-to-plasma exposure & sustained steady-state concentrations of the active metabolite (PALI-0008) above IC90 at #DDW2026 https://t.co/4zMYNuNXoy $PALI

[Palisade Bio @PalisadeBio]

Attending Digestive Disease Week® (DDW) 2026? Data from Palisade's lead program, PALI-2108, will be presented tomorrow, May 5th from 12:30-1:30 PM CDT. Learn more: https://t.co/U1rxcdamGk

$PALI #DDW2026

[Palisade Bio @PalisadeBio]

Data from Palisade's lead program, PALI-2108, will be presented at Digestive Disease Week® (DDW) 2026 on Tuesday, May 5th from 12:30-1:30 PM CDT. For poster presentation details: https://t.co/U1rxcdamGk

$PALI #DDW2026

[Palisade Bio @PalisadeBio]

Tune-in today, April 16th at 2:15 PM ET for a presentation from JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, at the Needham & Co. 25th Annual Healthcare Conference: https://t.co/bNSH73E5Qd $PALI

[Palisade Bio @PalisadeBio]

Palisade Bio today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week® (DDW) 2026, taking place May 2–5, 2026 in Chicago. For details: https://t.co/U1rxcdamGk

$PALI #DDW2026

[Palisade Bio @PalisadeBio]

On Thursday, April 16th at 2:15 PM ET, JD Finley, CEO, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, will present at the Needham & Co. 25th Annual Healthcare Conference. Register for the webcast here: https://t.co/bNSH73E5Qd $PALI

[Palisade Bio @PalisadeBio]

JD Finley, CEO, and Dr. Mitchell Jones, President & Chief Medical Officer of Palisade Bio, will present at the Needham & Co. 25th Annual Healthcare Conference on Thursday, April 16th from 2:15 PM to 2:55 PM ET in Track 3. For details: https://t.co/dcTYg1rVcn $PALI

[Palisade Bio @PalisadeBio]

Positive topline data from Palisade's Ph. 1b clinical study of PALI-2108 in FSCD support the continued development of PALI-2108 as a potential first therapy designed to address both inflammatory and fibrotic components of Crohn’s disease. Learn more: https://t.co/8F8ghFh24F $PALI

[Palisade Bio @PalisadeBio]

Mitch Jones, MD, Ph.D., President & Chief Medical Officer of Palisade will present positive topline data from the Phase 1b clinical study of PALI-2108 in FSCD today, April 1st, at the 4th Annual Precision Medicine in IBD Summit. For key clinical findings: https://t.co/8F8ghFh24F

[Palisade Bio @PalisadeBio]

“These positive data represent an important step in advancing PALI-2108 as a potential first therapy designed to address fibrostenotic complications in Crohn’s disease,” said Mitch Jones, MD, Ph.D., $PALI President & Chief Medical Officer. Read more: https://t.co/8F8ghFh24F

[Palisade Bio @PalisadeBio]

Tune-in today, March 31st at 8 AM ET for Palisade's webcast discussing the positive topline data from the Phase 1b clinical study evaluating PALI-2108 in patients with #FibrostenoticCrohnsDisease. For webcast details: https://t.co/myYIUkUvCF $PALI

[Palisade Bio @PalisadeBio]

Palisade today announced positive topline data from its Phase 1b clinical study evaluating PALI-2108 in patients with #FibrostenoticCrohnsDisease. Management will host a conference call and webcast tomorrow, March 31st at 8:00 AM ET, for details: https://t.co/8F8ghFh24F $PALI